Who are Belatacept MI (more intensive)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Belatacept LI (less intensive).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/belatacept-mi-more-intensive.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Belatacept MI (more intensive) — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Belatacept MI (more intensive) (Belatacept MI (more intensive)) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: T-cell costimulation blocker. Area: Immunology.

phase 3 T-cell costimulation blocker CD80/CD86 (via CTLA4-Ig fusion protein) Immunology Small molecule Live · refreshed every 30 min

Target snapshot

Belatacept MI (more intensive) (Belatacept MI (more intensive)) — Bristol-Myers Squibb. Belatacept is a selective T-cell costimulation blocker that inhibits CD80/CD86 binding to CD28, preventing T-cell activation and proliferation.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Belatacept MI (more intensive) TARGET	Belatacept MI (more intensive)	Bristol-Myers Squibb	phase 3	T-cell costimulation blocker	CD80/CD86 (via CTLA4-Ig fusion protein)
Belatacept LI (less intensive)	Belatacept LI (less intensive)	Bristol-Myers Squibb	phase 3	T-cell costimulation blocker	CD80/CD86 (via CTLA4-Ig fusion protein)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (T-cell costimulation blocker class)

Bristol-Myers Squibb · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Belatacept MI (more intensive) — Competitive Intelligence Brief. https://druglandscape.com/ci/belatacept-mi-more-intensive. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab